Abstract
Exercise therapy, especially when supervised on-site in a clinical facility or directed off-site for a home-based program, is an essential component of the management of coronary artery disease (CAD) and peripheral arterial disease (PAD). In the case of both atherosclerotic diseases, it can decrease adverse cardiovascular (CV) events. There has been a recent push toward invasive management of both CAD and PAD but accumulating clinical experience has shown the limitation of invasive management and emphasized the importance of medications, CV risk reduction, conditioning, and exercise, especially when supervised. Exercise results in increased peak oxygen consumption (V02), improvement of wellestablished CV risk factors such as plasma lipids, and an improvement in indicators of inflammation and of various metabolic factors. Fortunately, there is generally good third-party coverage of medications and vascular interventions but unfortunately, poor insurance coverage for supervised or directed exercise programs for which significant patient benefit has been established.
Keywords: Cardiovascular risk reduction, claudication, coronary artery disease, exercise training, low-density lipoprotein cholesterol, major adverse cardiac event, peripheral arterial disease, secondary prevention.
Graphical Abstract
Current Vascular Pharmacology
Title:Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Volume: 14 Issue: 5
Author(s): Thomas F. Whayne and Debabrata Mukherjee
Affiliation:
Keywords: Cardiovascular risk reduction, claudication, coronary artery disease, exercise training, low-density lipoprotein cholesterol, major adverse cardiac event, peripheral arterial disease, secondary prevention.
Abstract: Exercise therapy, especially when supervised on-site in a clinical facility or directed off-site for a home-based program, is an essential component of the management of coronary artery disease (CAD) and peripheral arterial disease (PAD). In the case of both atherosclerotic diseases, it can decrease adverse cardiovascular (CV) events. There has been a recent push toward invasive management of both CAD and PAD but accumulating clinical experience has shown the limitation of invasive management and emphasized the importance of medications, CV risk reduction, conditioning, and exercise, especially when supervised. Exercise results in increased peak oxygen consumption (V02), improvement of wellestablished CV risk factors such as plasma lipids, and an improvement in indicators of inflammation and of various metabolic factors. Fortunately, there is generally good third-party coverage of medications and vascular interventions but unfortunately, poor insurance coverage for supervised or directed exercise programs for which significant patient benefit has been established.
Export Options
About this article
Cite this article as:
Whayne F. Thomas and Mukherjee Debabrata, Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes, Current Vascular Pharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570161114999160719104936
DOI https://dx.doi.org/10.2174/1570161114999160719104936 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Current Application of Cyclosporine A to Investigate Skeletal Muscle Adaptation
Current Enzyme Inhibition